Ratings Huvitz Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
11,780 ^KRW	-0.67%		-4.46%	-38.16%

2023	Huvitz Co., Ltd.(KOSDAQ:A065510) added to S&P Global BMI Index	CI
2023	Huvitz Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

The company's profit outlook over the next few years is a strong asset.
Its low valuation, with P/E ratio at 6.16 and 5.06 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past four months, analysts' average price target has been revised downwards significantly.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HUVITZ CO., LTD.	-38.16%	92.06M		-
QUIDELORTHO CORPORATION	-54.19%	2.26B		C+
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+19.59%	1.89B		-
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-8.65%	1.52B		-
BIOTAGE AB	+17.35%	1.19B		B+
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-24.23%	871M		-
REVENIO GROUP OYJ	+1.25%	781M		-
CONTEC MEDICAL SYSTEMS CO.,LTD	-34.22%	750M	-	C-
VAREX IMAGING CORPORATION	-29.46%	591M		B+
CELLAVISION AB	+16.98%	560M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality